Literature DB >> 17638564

Effects of commonly used hemostatic agents on the porcine collecting system.

Isaac Yi Kim1, Louis Eichel, Robert Edwards, Carlos Uribe, David S Chou, Corollos Abdelshehid, Mike Ahlering, Shannon White, Edward Woo, Elspeth McDougall, Ralph V Clayman.   

Abstract

PURPOSE: Topical hemostatic agents have been particularly useful for preventing bleeding in tubeless percutaneous nephrolithotomy. In the present study, we investigated the effect of gelatin matrix hemostatic sealant (FloSeal), fibrin glue (Tisseel,), polyethylene glycol polymers (CoSeal), and bovine serum albumin/ glutaraldehyde (BioGlue) in the pig urinary collecting system after injection through a percutaneous nephrostomy (PCN) tract.
MATERIALS AND METHODS: Percutaneous nephrostomy was performed in 40 kidneys in 24 domestic pigs. Animals were divided into four groups of six each: (1) FloSeal; (2) Tisseel; (3) CoSeal; and (4) BioGlue. In 16 animals that tolerated the procedure, the contralateral kidney was used as a control for PCN only. All tracts were dilated to 30F with the Amplatz dilator, and 2 mL of the hemostatic agent was injected into the collecting system before pulling back to seal the puncture.
RESULTS: Among the control PCN kidneys, no obstruction was detected at the end of a 5-day period. However, three of six kidneys injected with FloSeal, Tisseel, or CoSeal and four of six kidneys injected with BioGlue were obstructed. In each of these cases, there was an associated retroperitoneal urinoma.
CONCLUSION: FloSeal, Tisseel, CoSeal, and BioGlue, if injected directly into the porcine collecting system, can result in significant obstruction that does not resolve over a 5-day period. Until there are clinical data to the contrary, we believe that when using one of these hemostatic agents in association with a tubeless percutaneous procedure, a retrograde occlusion balloon catheter should be considered to prevent inadvertent injection of these materials into the collecting system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638564     DOI: 10.1089/end.2007.9960

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  6 in total

1.  Current Status of Hemostatic Agents and Sealants in Urologic Surgical Practice.

Authors:  Sashi S Kommu; Robert McArthur; Amr M Emara; Utsav D Reddy; Christopher J Anderson; Neil J Barber; Raj A Persad; Christopher G Eden
Journal:  Rev Urol       Date:  2015

Review 2.  The management of the access tract after percutaneous nephrolithotomy.

Authors:  Tanja Hüsch; Michael Reiter; René Mager; Eva Steiner; Thomas R W Herrmann; Axel Haferkamp; David Schilling
Journal:  World J Urol       Date:  2015-04-23       Impact factor: 4.226

3.  Tubeless percutaneous nephrolithotomy with non-absorbable hemostatic sealant (Quikclot®) versus nephrostomy tube placement: a propensity score-matched analysis.

Authors:  Kyo Chul Koo; Sang Un Park; Ho Sung Jang; Chang-Hee Hong
Journal:  Urolithiasis       Date:  2015-06-30       Impact factor: 3.436

Review 4.  Hemostatic agents used for nephrostomy tract closure after tubeless PCNL: a systematic review and meta-analysis.

Authors:  Cui Yu; Zhou Xu; Wang Long; Liu Longfei; Zeng Feng; Qi Lin; Zu Xiongbing; Chen Hequn
Journal:  Urolithiasis       Date:  2014-07-27       Impact factor: 3.436

5.  Bovine serum albumin glutaraldehyde for completely sutureless laparoscopic heminephrectomy in a survival porcine model.

Authors:  Michael K Louie; Aldrin Joseph R Gamboa; Adam G Kaplan; Amanda Khosravi; Hung Truong; Lorena Andrade; Rachelle Lin; Reza Alipanah; Cervando Ortiz; David McCormick; Geoffrey N Box; Hak J Lee; Leslie A Deane; Robert A Edwards; Elspeth M McDougall; Ralph V Clayman
Journal:  J Endourol       Date:  2010-03       Impact factor: 2.942

6.  Use of biological Glue (Bioglue®) in laparoscopic partial nephrectomy: a study in pigs.

Authors:  Luis Felipe Brandão; Fabio Cesar Miranda Torricelli; Glauco Melo; Luiz Cesar Fernando Takano; Anuar Ibrahim Mitre; Marco Antonio Arap
Journal:  Int Braz J Urol       Date:  2015 Mar-Apr       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.